News

A new study led by researchers at Oxford and Guangdong Centre for Diseases Control and Prevention describes the epidemiology and genetic make-up of the COVID-19 outbreak in China’s most populous region, and shows how early and intensive testing and tracing helped to interrupt local transmission of the virus.

Researchers have identified the genetic basis of rapid adaptation using a native fish species, revealing that changes in the genome can be observed within a single generation.

Scientists at the HudsonAlpha Institute for Biotechnology, the University of California, San Francisco (UCSF) and the University of Alabama at Birmingham (UAB), have identified a new risk factor for multiple neurodegenerative diseases.

A new study published in the journal Nature Communications outlines the creation of the first experimental mouse model allowing for direct analysis of the mechanical function of proteins in living organisms. Technology Networks spoke with the research team leader to find out more.

Researchers have shown that genome-editing techniques could eliminate up to 70 percent of the contaminating protein by mass in recombinant-protein drugs.

Researchers have discovered a new type of immune cell that helps to keep breast tissue healthy by regulating a vital process within mammary ducts – the sites where milk is produced and transported, but also where most breast cancers arise.

Researchers have successfully decoded the genome of the herpes simplex virus 1, uncovering hundreds of previously unknown gene products.

By shuffling DNA in and out of one gene, syphilis stays a step ahead of the immune system to resist eradication

The interferon-stimulated gene C19orf66 plays an important role in the defence against hepatitis C viruses. A research team has now studied how C19orf66 works and found that C19orf66 disrupts the formation of the viral replication machinery.

New data from a Phase III trial found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.